Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial

Lancet Neurology

Volumn 6, Issue 10, 2007, Pages 878-886

  Di Prospero, Nicholas A ^a   Baker, Angela ^a   Jeffries, Neal ^a   Fischbeck, Kenneth H ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; IDEBENONE; PLACEBO;

ADOLESCENT; ANALYSIS OF VARIANCE; ANXIETY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DNA DAMAGE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPEPSIA; EPISTAXIS; FEMALE; FRIEDREICH ATAXIA; FRIEDREICH ATAXIA RATING SCALE; GASTROENTERITIS; HUMAN; INTERNATIONAL COOPERATIVE ATAXIA RATING SCALE; MALE; MYALGIA; NAUSEA; NEUTROPENIA; OXIDATIVE STRESS; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SPRAIN; THORAX PAIN;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ANTIOXIDANTS; BENZOQUINONES; CHILD; DEOXYGUANOSINE; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRIEDREICH ATAXIA; HUMANS; MALE; NERVOUS SYSTEM; NEUTROPENIA; SEVERITY OF ILLNESS INDEX; UBIQUINONE;

EID: 34548606803     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70220-X     Document Type: Article

References (23)

1. Filla A., De Michele G., Marconi R., et al. Prevalence of hereditary ataxias and spastic paraplegias in Molise, a region of Italy. J Neurol 239 (1992) 351-353
2. Durr A., Cossee M., Agid Y., et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 335 (1996) 1169-1175
3. Campuzano V., Montermini L., Molto M., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
4. Rotig A., de Lonlay P., Chretien D., et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17 (1997) 215-217
5. Emond M., Lepage G., Vanasse M., and Pandolfo M. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 55 (2000) 1752-1753
6. Schulz J., Dehmer T., Schols L., et al. Oxidative stress in patients with Friedreich ataxia. Neurology 55 (2000) 1719-1721
7. Gillis J., Benefield P., and McTavish D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 5 (1994) 133-152
8. Rustin P., Rotig A., Munnich A., and Sidi D. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res 36 (2002) 467-469
9. Hausse A., Aggoun Y., Bonnet D., et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87 (2002) 346-349
10. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., and Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60 (2003) 1676-1679
11. Artuch R., Aracil A., Mas A., et al. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33 (2002) 190-193
12. Di Prospero N., Sumner C., Penzak S., Ravina B., Fischbeck K., and Taylor J. Safety, tolerability, and pharmacokinetics of high-dose idebenone administered to patients with Friedreich's ataxia. Arch Neurol 64 (2007) 803-808
13. Dizdaroglu M. Chemical determination of free radical-induced damage to DNA. Free Radic Biol Med 10 (1991) 225-242
14. Trouillas P., Takayanagi T., Hallett M., et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145 (1997) 205-211
15. Subramony S., May W., Lynch D., et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64 (2005) 1261-1262
16. Hollander M., and Wolfe D. Nonparametric statistical methods. 2nd edn. (1999), Wiley, New York
17. Bogdanov M., Beal M., McCabe D., Griffin R., and Matson W. A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2′-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods. Free Radic Biol Med 27 (1999) 647-666
18. Piemonte F., Pastore A., Tozzi G., et al. Glutathione in blood of patients with Friedreich's ataxia. Eur J Clin Invest 31 (2001) 1007-1011
19. Bradley J., Homayoun S., Hart P., Schapira A., and Cooper J. Role of oxidative damage in Friedreich's ataxia. Neurochem Res 29 (2004) 561-567
20. Buyse G., Mertens L., Di Salvo G., et al. Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60 (2003) 1679-1681
21. Zs-Nagy I. Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review. Arch Gerontol Geriatr 11 (1990) 177-186
22. Seznec H., Simon D., Monassier L., et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 13 (2004) 1017-1024
23. Jauslin M., Wirth T., Meier T., and Schoumacher F. A cellular model for Friedreich ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet 11 (2002) 3055-3063